Organization
Caris Life Sciences
6 abstracts
Abstract
The genomic and transcriptomic landscapes of chemotherapy naïve vs post-chemotherapy germ cell tumors.Org: University of California San Diego Health, CanSino Biologics, La Jolla, CA, UT Southwestern Medical Center, Txinno Bioscience,
Abstract
Kinome reprogramming as a therapeutic opportunity in ESR1 fusion driven breast cancer but not in gynecologic cancers.Org: Caris Life Sciences Research and Development, Tempero Bio, Azidus Brasil, Caris Life Sciences, Phoenix Tissue Repair,
Abstract
Molecular and immunological characterization of androgen receptor expression in different breast cancer subtypes.Org: Norris Comprehensive Cancer Center, Keck School of Medicine, Caris Life Sciences, City of Hope National Medical Center, Department of Population and Public Health Sciences,
Abstract
Adjunctive statistical standardization of quantitated adjuvant ER and PgR in CCTG MA.27.Org: Ontario Institute for Cancer Research, Toronto, ON, Canada, MASS General Hospital BHX-1, Mayo Clinic Department of Oncology, Progendis, Caris Life Sciences,
Abstract
Therapeutic insights for the aggressive subset of high-grade gliomas (HGG) driven by chromosome 1q32 MDM4-containing amplicon and unmethylated MGMT.Org: Legorreta Cancer Center at Brown University, Brown University School of Medicine-Rhode Island Hospital, University of Minnesota, Sarah Cannon Research Institute/Tennessee Oncology, Brown Unversity School of Medicine-Rhode Island Hospital,
Abstract
Unraveling the immunologic vulnerabilities of diffuse hemispheric glioma, H3 G34-mutant.Org: University of Minnesota, Caris Life Sciences, Duke University Medical Center, The Preston Robert Tisch Brain Tumor Center, Miami Cancer Institute,